Dr. Konstantinopoulos on Immunotherapy in Ovarian Cancer
March 8th 2019Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.
Read More
Dr. Konstantinopoulos on Immunotherapy in Gynecologic Cancers
December 15th 2018Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses immunotherapy in gynecologic cancers.
Read More
Dr. Konstantinopoulos Discusses PARP Plus Immunotherapy
September 22nd 2018Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the combination of PARP inhibitors and immunotherapy.
Read More
Dr. Konstantinopoulos on Rationale for TOPACIO Trial in Ovarian Cancer
July 25th 2018Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.
Read More